Using AI to predict early return of multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study uses artificial intelligence to analyze how multiple myeloma may lead to early relapse. It may help doctors better predict and manage the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have active multiple myeloma
- You agree to sign a consent form for the study and data use
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
This trial is testing a new type of blood test (called a liquid biopsy) to find multiple myeloma early by looking at tiny pieces of DNA in your blood. It is for people already diagnosed with multiple myeloma, smoldering multiple myeloma, or MGUS.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This study uses MRI scans to check the body for signs of multiple myeloma after a stem cell transplant and before maintenance therapy. It aims to see if MRI can help predict how well the treatment works.
This early-stage trial tests a new drug called QI-019B in patients whose multiple myeloma (a blood cancer) has stopped responding to standard treatments. The study checks if QI-019B is safe and whether it helps slow or stop the cancer's growth.
This study uses already collected, de-identified data from past multiple myeloma trials to learn more about the disease. It does not involve any new treatments or procedures.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.